Clinical trials: Naloxone
Heroin Dependence, Opioid-Related Disorders
Buprenorphine and Naloxone Combination Study - 10
The purpose of this study is to examine pharmacokinetics and dose proportionality of sublingual tablets containing varying doses of buprenorphine and naloxone.
- Trial name
- NCT00015288
- Testing
- Buprenorphine/naloxone
- Where
- United States
- Sponsor
- National Institute on Drug Abuse (NIDA)
Drug Interaction, Analgesics
Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder
The purpose of this research study is to test the safety, tolerability, drug interactions with buprenorphine-naloxone, and effectiveness lemborexant when used to treat Opioid Use Disorder.
- Conditions
- Drug Interaction, Analgesics, Opioid Use Disorder
- Trial name
- NCT04818086
- Testing
- Lemborexant, Buprenorphine-naloxone
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Virginia Commonwealth University
Drug Overdose
Bioavailability of Nasal Naloxone and Injected Naloxone Compared
Opioid overdoses have in the last decade counted for about 230 untimely deaths annually in Norway. The government is currently implementing a strategy for combating this epidemic.
- Trial name
- OPI-15-002 (NCT02598856)
- Testing
- Intranasal (IN) naloxone 1x, Intranasal (IN) naloxone 2, Intravenous (IV) naloxone
- Where
- Norway
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Norwegian University of Science and Technology
Opioid Dependence
Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone
The investigators will randomize 50 opioid-dependent participants who have initially failed outpatient induction onto XR-NTX; participants will receive buprenorphine/naloxone on a weekly basis for 30 days.
- Trial name
- NCT02294253
- Testing
- Buprenorphine/naloxone
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Opioid-use Disorder
Mobile Medication Adherence Platform for Buprenorphine-Naloxone During Treatment of Opioid Use Disorder: Phase I Study
The investigators will conduct a phase I study involving 41 participants selected randomly among patients prescribed buprenorphine-naloxone for opioid misuse as a feasibility trial of the study of the Pillsy device.
- Trial name
- MAP4BUP (NCT04656899)
- Testing
- Reminders messages to improve adherence.
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Washington State University
Opiate Dependence
Naloxone Methadone Combination (NAMEKO)
The aim of the study is to examine the tolerability and abuse potential of the diluted methadone solution (5 mg/ml → 2 mg/ml) in combination with naloxone in opioid substitution treatment.
- Trial name
- NAMEKO (NCT01160432)
- Testing
- Methadone, naloxone
- Where
- Finland
- Sponsor
- Kuopio University Hospital
Drug Overdose, Opioid-Related Disorders
Buccal Versus Injectable Naloxone: a Phase I Healthy Volunteer Study
Naloxone is the standard treatment in response to cases of suspected opiate overdose. Buccal formulation of naloxone is a novel alternative to the licensed naloxone injection which, by removing the risk of accidental…
- Trial name
- NCT02733822
- Testing
- Naloxone
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- King's College London
Constipation, Impaction, and Bowel Obstruction, Unspecified Adult Solid Tumor, Protocol Specific
Naloxone in Treating Constipation in Patients Who Are Receiving Opioids for Chronic Pain
RATIONALE: Naloxone may be effective in treating constipation that may be caused by opioid pain medications such as morphine. PURPOSE: Phase III trial to determine the effectiveness of naloxone in relieving constiption in…
- Trial name
- NCT00020605
- Testing
- naloxone hydrochloride
- Where
- United States
- Sponsor
- Dana-Farber Cancer Institute
Analgesia
RM1 Project 1 - tAN Naloxone
This two-visit, randomized, double-blind, sham-controlled trial, uses a novel naloxone blockade model in 136 individuals to determine whether the analgesic effects of a 30-minute transcutaneous auricular neurostimulation (tAN)…
- Trial name
- NCT05490134
- Testing
- Naloxone, Saline
- Where
- United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
Back Pain, Low Back Pain
Tapentadol Prolonged Release (PR) Versus Oxycodone/Naloxone Prolonged Release in Severe Chronic Low Back Pain With a Neuropathic Component.
This was a clinical effectiveness trial designed to compare the effectiveness, safety, and tolerability of treatment with tapentadol prolonged release with that of oxycodone/naloxone prolonged release in non-opioid pre-treated…
- Conditions
- Back Pain, Low Back Pain, Neuropathic Pain
- Trial name
- NCT01838616
- Testing
- Tapentadol Prolonged Release, Oxycodone/Naloxone Prolonged Release
- Where
- 50 sites in Austria, Germany and 2 more
- Volunteers
- 367 people
- Sponsor
- Grünenthal GmbH
Healthy Subjects, Hyperalgesia
Effect of High-dose Naloxone Following Third Molar Extraction
Recent studies have focused on the role of endogenous opioids on central sensitization. Central sensitization is known to be impaired or altered in chronic pain conditions, as fibromyalgia or chronic tension headache.
- Conditions
- Healthy Subjects, Hyperalgesia, Inflammations, Endodontic, Pain, Acute
- Trial name
- TME (NCT02976337)
- Testing
- Naloxone, Normal Saline
- Where
- Denmark
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- mads u werner
Opioid-use Disorder
Evaluating Buprenorphine/Naloxone Microdosing vs. Standard Dosing in Emergency Departments
This is a multi-centre, open-label RCT at four Emergency Departments (EDs) in British Columbia and Alberta. The purpose of the current study is to compare the effectiveness of buprenorphine/naloxone microdosing and standard…
- Trial name
- NCT04893525
- Testing
- Buprenorphine/naloxone
- Where
- 6 sites in Canada
- Volunteers
- 658 people
- Sponsor
- University of British Columbia
Healthy Volunteer - Complete
Proof of Concept (PoC) Evaluation of Naloxone Unique Intramuscular (IM) Injection
WHAT IS THE PURPOSE OF THIS RESEARCH STUDY This research study is designed to demonstrate that intramuscular (IM) Injection of FDA Approved Naloxone Hydrochloride (HCI) given in the forearm muscle is approximately the same as…
- Trial name
- NCT07180420
- Testing
- naloxone IM
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- STAT Therapeutics Inc
Opioid Overdose
Improving Availability of Intranasal Naloxone
While there is a lifesaving medication called naloxone that can reverse the deadly effects of opioid overdose, patients often fail to fill the prescription at the pharmacy when it is prescribed.
- Trial name
- NCT05877118
- Testing
- Enhanced Overdose Education (EOE), Standard education
- Where
- 2 sites in United States
- Volunteers
- 84 people
- Sponsor
- Hartford Hospital
Pathological Gambling, Gambling Disorder
Effects of Intranasal Naloxone on Gambling Urges and Craving in Gambling Disorder
Primary objective: *To determine whether treatment with naloxone hydrochloride nasal spray reduces gambling urge symptoms in patients with gambling disorder The secondary objectives of the study are: To determine the effects of…
- Conditions
- Pathological Gambling, Gambling Disorder, Opioid Antagonist, Naloxone
- Trial name
- NalGamb (NCT03430180)
- Testing
- Naloxone hydrochloride
- Where
- Finland
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Finnish Institute for Health and Welfare
Healthy Males
Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function
This is a double-blind, randomized, study at a single clinical site investigating the effect of methylnaltrexone and naloxone versus placebo in healthy males who have received a short-acting opioid, remifentanil.
- Trial name
- NCT01367561
- Testing
- Naloxone, IV Methylnaltrexone (MNTX)
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Opioid-related Disorders
Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone
The purpose of this study is to compare the presence, degree, time course and profile of opioid withdrawal symptoms associated with induction onto new formulations of buprenorphine or buprenorphine/naloxone in persons with active…
- Trial name
- NCT00637000
- Testing
- Buprenorphine soluble film, Buprenorphine/naloxone film strip
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Indivior Inc.
Heroin Dependence, Opioid-Related Disorders
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1 - 1
The purpose of this study is to assess the clinical efficacy of the buprenorphine/naloxone combination tablet for alternate-day dosing and determine whether multiples of the daily dose are necessary to maintain an effective…
- Trial name
- NCT00000326
- Testing
- Heroin Dependence
- Where
- United States
- Sponsor
- University of Colorado, Denver
Spinal Disorders
An Interventional Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Spinal Disorders
Study Objectives: 1. Primary objective To assess the pain reduction after 8 weeks treatment from baseline (week 0) 2. Secondary objectives To assess the pain reduction after 4 weeks treatment from baseline (week 0) To assess the…
- Trial name
- TALENT (NCT01811238)
- Testing
- Oxycodone/naloxone
- Volunteers
- 240 people
- Sponsor
- Mundipharma Korea Ltd
Healthy
Evaluation Of PF-00572778 And Alprazolam On Naloxone Challenge In Healthy Subjects
PF-00572778, a CRH antagonist, is expected to attenuate adrenocorticotropin (ACTH) and cortisol responses to naloxone by blocking the effect of the CRH increases induced by naloxone at the postsynaptic receptors.
- Trial name
- NCT00580190
- Testing
- alprazolam, PF-00572778
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Pfizer